June 2015
Volume 56, Issue 7
ARVO Annual Meeting Abstract  |   June 2015
Use of Systemic Immune Suppressive Agents in Pediatric Uveitis
Author Affiliations & Notes
  • Kruti Dajee
    Ophthalmology, University of Texas Southwestern, Dallas, TX
  • Roshni Patel
    Ophthalmology, University of Texas Southwestern, Dallas, TX
  • Cassidy Tang
    Ophthalmology, University of Texas Southwestern, Dallas, TX
  • Monica Bratton
    Ophthalmology, University of Texas Southwestern, Dallas, TX
  • Yu-Guang He
    Ophthalmology, University of Texas Southwestern, Dallas, TX
  • Footnotes
    Commercial Relationships Kruti Dajee, None; Roshni Patel, None; Cassidy Tang, None; Monica Bratton, None; Yu-Guang He, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 6208. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kruti Dajee, Roshni Patel, Cassidy Tang, Monica Bratton, Yu-Guang He; Use of Systemic Immune Suppressive Agents in Pediatric Uveitis. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):6208.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Pediatric uveitis is a blinding disease and is challenging to treat in the pediatric population. There are few FDA approved systemic immunosuppressive medications approved for use in pediatric uveitis. The purpose of this study is to demonstrate efficacy and safety of these agents in pediatric uveitis.

Methods: A retrospective chart review was conducted at Children’s Medical Center from 2001-2014. Ophthalmology and rheumatology visits of 35 patients were reviewed. To demonstrate efficacy of immunosuppressive agents, visual acuity, anterior chamber cell and flare, ocular complications, and dependency on topical and oral corticosteroids were recorded. To demonstrate safety, serious and minor adverse events and effect on pediatric growth and well-being were analyzed.

Results: Systemic immunosuppressives used for treatment included methotrexate (40.0%), adalimumab (17.1%), mycophenolate mofetil (5.7%), and infliximab (2.9%). The mean follow up period was 36.8 months. Mean visual acuity at treatment initiation was 20/80, which improved to 20/50. Average anterior chamber cell and flare improved (-1.08 and -0.76 respectively). Dependency on oral steroids reduced from 8.6% to 5.7%. Frequency of topical steroids improved from 6.7 times a day to 2.6 times a day at the last follow up visit (p=0.0001, CI 2.42 to 5.70). An overall reduction in number of ocular complications was noted from 80.0% to 60.0%. 11.4% patients were noted to have serious adverse events that led to discontinuation of the immunosuppressive agent. 51.4% patients reported minor adverse events. The average height percentile was 55.52 (SD=30.59), weight was 68.41 (SD=30.15), and BMI was 68.94 (SD=33.40).

Conclusions: This study aims at providing a comprehensive review on the safety and efficacy of the use of systemic immunosuppressives in the management of pediatric uveitis. While other major studies have detailed characteristics and complications occurring with pediatric uveitis; to our knowledge, this is the first study of its kind to focus on the use of immunosuppressives in pediatric uveitis at a large tertiary referral center. Our study shows that the use of immunosuppressive agents is efficacious in improving visual outcomes, decreasing the need for topical steroids, decreasing inflammation and ocular complications. They are also safe given the limited number of adverse events with no significant effect on pediatric well-being.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.